News

Introduce our readers to R5 Capital by telling us a bit about the business overall. Mr. Mushkin: R5 Capital is a consumer research and consulting firm. It was formed roughly five and a half years ago.
Let’s start with an introduction of sorts to CS McKee — your overall business, portfolios, and investment approach — before we get into a specific fund. Mr. Thompson: At CS McKee, we’re primarily an ...
Let’s start with an overview of the Global High Dividend Low Volatility Fund (NAWGX) that you manage — a high-level snapshot of what the portfolio looks like and what the key elements or ...
I thought a good place to start would be with you, Craig, telling our readers a bit about Icon Advisers, the company overall and what the business looks like today. It’s almost 40 years ago that you ...
For our readers, let’s start with some introductory information about Phocas Financial, an overview of the firm’s history and what the business looks like today. Ms. Foreman: Phocas is an ...
Interview with the Chairman and CEO: MAIA Biotechnology Inc. (NYSEAMERICAN:MAIA) Vlad Vitoc Interview with the Chairman and CEO: Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) and Telomir ...
The Wall Street Transcript is a completely unique resource for investors and business researchers.
Please update us on what you’re doing now. It looks like you founded a new firm. Mr. Singh: I left Oppenheimer last year, after an 18-year career; 10 years on the sell side, and 15 total between buy- ...
We’ve spoken before, but just for readers who may not be familiar, let’s start with a refresher on the company, its mission, and some milestones. Mr. Do: BioVie has two assets that we are currently ...
Alan H. Auerbach has served as Chairman of the Board and as CEO and President of Puma Biotechnology, Inc. since its inception. Before joining Puma, Mr. Auerbach served as Founder, CEO, President ...
Steven M. Lichtman is Managing Director and Senior Analyst for medical devices at Oppenheimer & Co. Inc. Mr. Lichtman has been on the sell side following the medical devices sector for over 20 ...
Jason Wittes is a Managing Director and Senior Research Analyst at Roth Capital Partners. He has over 20 years of health care investment experience on both the buy side and sell side. Prior to ...